Week 52Week 104
OL AdalimumabOL Adalimumab
PSpARC40 (%)a64.872.1
ASDAS inactive disease (%)b54.559.1
% Leeds remissionc68.166.3
% SPARCC remissiond54.457.4
% MASES remissione58.362.5
% SJC76=0f59.062.3
% TJC78=0g39.251.9
% SJC=0, TJC=0 and total enthesitis count=0h24.629.1

  • Observed data. N=Week 52/Week 104:

  • ↵a N=145/129;

  • ↵b N=143/127;

  • ↵c N=91/80;

  • ↵d N=114/101;

  • ↵e N=108/96;

  • ↵f N=134/122;

  • ↵g N=143/129;

  • ↵h N=114/103.